Japan becomes first country to approve Regeneron antibody cocktail (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19

Regeneron Pharmaceuticals

20 July 2021 - Regeneron Pharmaceuticals today announced that Japan's Ministry of Health, Labour and Welfare has approved Regeneron's casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19. 

This marks the first time the antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve in other countries, has received a full approval to treat COVID-19. 

Emergency or temporary pandemic use authorisations are currently in place in more than 20 countries, including in the U.S., European Union, India, Switzerland and Canada.

Read Regeneron Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder